SPOTLIGHT -
COVID-19 restrictions linked to reduced preterm birth rates
In a recent study, very preterm birth rates were reduced during COVID-19 lockdown periods vs prepandemic periods.
Read More
How Individually Identifying More HPV Types Enables Better Patient Management and More Precise Care
Listen
Safety and efficacy of fezolinetant proven in Hispanic women
New research shows fezolinetant significantly reduces the frequency and severity of hot flashes in Hispanic women, offering a safer alternative to hormone replacement therapy.
The Importance of Including Hemoglobinopathies as a Part of Carrier Screening Panels
FDA updates warning for liver injury due to fezolinetant
The FDA upped the recommended rate of liver blood tests for patients initiating fezolinetant on the basis of a post-marketing case report involving serious liver injury.
Investigational nasal spray shows promise vasomotor symptom treatment
PH80 nasal spray shows promise in reducing menopausal hot flashes, offering an effective and safe non-hormonal treatment option.
